Literature DB >> 15182771

Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC).

A Bergström1, B Andersson, M Edner, E Nylander, H Persson, U Dahlström.   

Abstract

AIM: The purpose of this study was to investigate the effects of carvedilol on diastolic function (DF) in heart failure patients with preserved left ventricular (LV) systolic function and abnormal DF. PATIENTS AND METHODS: We randomised 113 patients with diastolic heart failure (DHF) (symptomatic, with normal systolic LV function and abnormal DF) into a double blind multi-centre study. The patients received either carvedilol or matching placebo in addition to conventional treatment. After uptitration, treatment was continued for 6 months. Two-dimensional and Doppler echocardiography were used for quantification of LV function at baseline and at follow-up. Four different DF variables were evaluated by Doppler echocardiography: mitral flow E:A ratio, deceleration time (DT), isovolumic relaxation time (IVRT) and the ratio of systolic/diastolic pulmonary venous flow velocity (pv-S/D). Primary endpoint was change in the integrated quantitative assessment of all four variables during the study.
RESULTS: Ninety-seven patients completed the study. A mitral flow pattern reflecting a relaxation abnormality was recorded in 95 patients. There was no effect on the primary endpoint, although a trend towards a better effect in carvedilol treated patients was noticed in patients with heart rates above 71 beats per minute. At the end of the study, there was a statistically significant improvement in E:A ratio in patients treated with carvedilol (0.72 to 0.83) vs. placebo (0.71 to 0.76), P<0.05.
CONCLUSIONS: Treatment with carvedilol resulted in a significant improvement in E:A ratio in patients with heart failure due to a LV relaxation abnormality. E:A ratio was found to be the most useful variable to identify diastolic dysfunction in this patient population. This effect was observed particularly in patients with higher heart rates at baseline.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15182771     DOI: 10.1016/j.ejheart.2004.02.003

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  53 in total

Review 1.  Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials.

Authors:  Ambarish Pandey; Akhil Parashar; Dharam Kumbhani; Sunil Agarwal; Jalaj Garg; Dalane Kitzman; Benjamin Levine; Mark Drazner; Jarett Berry
Journal:  Circ Heart Fail       Date:  2014-11-16       Impact factor: 8.790

Review 2.  Novel paradigms in the therapeutic management of heart failure with preserved ejection fraction: clinical perspectives.

Authors:  Fayez El Shear
Journal:  Am J Cardiovasc Dis       Date:  2019-10-15

3.  Preliminary clinical study of real-time three-dimensional echocardiographic volume-time curve in evaluating left ventricular diastolic function.

Authors:  Hongwen Fei; Yale He; Yueshuang Hou; Yan Xu; Xinsheng Huang; Bixia Feng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-08

4.  Heart failure with mid-range ejection fraction and with preserved ejection fraction.

Authors:  J Petutschnigg; F Edelmann
Journal:  Herz       Date:  2018-08       Impact factor: 1.443

Review 5.  Therapeutic approaches to diastolic dysfunction.

Authors:  Rajesh Janardhanan; Akshay S Desai; Scott D Solomon
Journal:  Curr Hypertens Rep       Date:  2009-08       Impact factor: 5.369

Review 6.  Pharmacotherapy of heart failure with normal ejection fraction (HFNEF)--a systematic review.

Authors:  Sujit Rajagopalan; Anjuman Arora; Nusrat Shafiq; Srinivas Reddy S; Promila Pandhi; Niti Mittal; Samir Malhotra
Journal:  Br J Clin Pharmacol       Date:  2011-09       Impact factor: 4.335

Review 7.  Pharmacological Treatment of Heart Failure with Preserved Ejection Fraction.

Authors:  Kazuhiro Yamamoto
Journal:  Yonago Acta Med       Date:  2017-06-26       Impact factor: 1.641

8.  Comparison of β-blocker effectiveness in heart failure patients with preserved ejection fraction versus those with reduced ejection fraction.

Authors:  Mostafa El-Refai; Edward L Peterson; Karen Wells; Tanmay Swadia; Hani N Sabbah; John A Spertus; L Keoki Williams; David E Lanfear
Journal:  J Card Fail       Date:  2013-02       Impact factor: 5.712

Review 9.  Current Management and Future Directions of Heart Failure With Preserved Ejection Fraction: a Contemporary Review.

Authors:  Chayakrit Krittanawong; Marrick L Kukin
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-03-20

10.  Blunted frequency-dependent upregulation of cardiac output is related to impaired relaxation in diastolic heart failure.

Authors:  Rolf Wachter; Stephan Schmidt-Schweda; Dirk Westermann; Heiner Post; Frank Edelmann; Mario Kasner; Claus Lüers; Paul Steendijk; Gerd Hasenfuss; Carsten Tschöpe; Burkert Pieske
Journal:  Eur Heart J       Date:  2009-12       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.